Notably, the selective inhibition of YAP in macrophages through Dopamine receptor D2 (DRD2) antagonism has demonstrated promise in preventing liver fibrosis, making it a potential candidate for treating nonalcoholic steatohepatitis (NASH) (69). The gene discussed is YAP1; the disease is metabolic dysfunction-associated steatohepatitis.